Clinical Trial: Diet and PSA Levels in Patients With Prostate Cancer

This study is no longer recruiting patients.

Sponsors and Collaborators: National Cancer Institute (NCI)
Memorial Sloan-Kettering Cancer Center
Information provided by: National Cancer Institute (NCI)

Purpose

RATIONALE: The amount of fat, fiber, soy, fruits, vegetables, vitamin E, and green tea in the diet may affect androgen metabolism in men. This may affect PSA level in patients with prostate cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of two diets, differing in fat, fiber, soy, fruit, vegetable, vitamin E, and green tea content, in affecting PSA level in patients with prostate cancer.

Condition Treatment or Intervention Phase
stage II prostate cancer
stage III prostate cancer
stage IV prostate cancer
stage I prostate cancer
adenocarcinoma of the prostate
recurrent prostate cancer
prevention of prostate cancer
 Procedure: dietary intervention
 Drug: chemoprevention of cancer
 Procedure: cancer prevention intervention
 Procedure: complementary and alternative therapy
 Drug: green tea extract
 Drug: soy protein isolate
 Drug: vitamin E
Phase III

MedlinePlus related topics:  Prostate Cancer

Study Type: Interventional
Study Design: Treatment

Official Title: Phase III Randomized Study of the Effect of a Diet Low in Fat and High in Soy, Fruits, Vegetables, Green Tea, Vitamin E, and Fiber on PSA Levels in Patients With Prostate Cancer

Further Study Details: 

Study start: April 1998

OBJECTIVES: I. Determine the effects of 2 dietary regimens on levels of prostate-specific antigen (PSA) in patients with prostate cancer. II. Determine the compliance of these patients with the dietary regimen. III. Evaluate the effects of the dietary regimen on quality of life in these patients. IV. Evaluate the effects of the dietary regimen on PSA anxiety in these patients. V. Evaluate the effects of the dietary regimen on obesity, high blood pressure, and serum cholesterol in these patients.

PROTOCOL OUTLINE: This is a randomized study. Patients are stratified according to previous treatment (prostatectomy vs radiotherapy) and prostate-specific antigen (PSA) level (less than 5 mg/mL vs 5 or greater mg/mL). All patients complete quality of life, dietary, and other questionnaires before, during, and at the conclusion of the study. Patients are randomized to one of two dietary intervention regimens: Arm I (Intensive Nutritional Intervention): Patients are assigned to follow a low fat, high fiber diet that is also high in soy, fruits and vegetables, green tea, and vitamin E. Patients meet with a nutritionist for nutrition education and dietary counseling weekly for 8 weeks, then every 2 weeks for 2 months, and then monthly for 14 months. Sessions include dietary counseling, meal planning, and instruction in skills necessary to maintain dietary lifestyle changes. Patients record their dietary intake on a regular basis. Arm II (General Nutritional Instruction): Patients are assigned to follow dietary guidelines established by the National Cancer Institute. Patients meet with a nutritionist for dietary counseling and monitoring every 2 months for 18 months. Patients on both arms have PSA levels tested before the study, 1 and 3 months into the study, and then every 3 months thereafter for up to 18 months.

PROJECTED ACCRUAL: A total of 154 patients will be accrued for this study over 2 years.

Eligibility

Ages Eligible for Study:  18 Years and above

Criteria

PROTOCOL ENTRY CRITERIA:

--Disease Characteristics--

--Prior/Concurrent Therapy--

  • Biologic therapy: Not specified
  • Chemotherapy: Not specified
  • Endocrine therapy: At least 4 weeks since hormone therapy
  • Radiotherapy: At least 4 weeks since radiotherapy
  • Surgery: Prior prostatectomy allowed
  • Other: Recovered from toxic effects of any prior therapy

--Patient Characteristics--

  • Age: 18 and over
  • Performance status: Karnofsky 70-100%
  • Life expectancy: At least 6 months
  • Hematopoietic: WBC greater than 3,500/mm3; Platelet count greater than 100,000/mm3
  • Hepatic: Bilirubin less than 2.0 mg/dL OR SGOT less than 3 times upper limit of normal (ULN)
  • Renal: Creatinine less than 2.0 mg/dL OR Creatinine clearance greater than 40 mL/min
  • Cardiovascular: No significant heart disease (New York Heart Association class III or IV)
  • Pulmonary: No severe debilitating pulmonary disease
  • Other: No narcotic dependent pain; No extreme dietary patterns (such as a macrobiotic diet); No baseline diet having fewer than 25% calories from fat; No history of second malignancy within past 5 years except nonmelanomatous skin cancer; No insulin-dependent diabetes; No infection requiring antibiotics

Location Information


New York
      Memorial Sloan-Kettering Cancer Center, New York,  New York,  10021,  United States

Study chairs or principal investigators

Moshe Shike,  Study Chair,  Memorial Sloan-Kettering Cancer Center   

More Information

Clinical trial summary from the National Cancer Institute's PDQ® database

Study ID Numbers:  CDR0000066354; MSKCC-98014; NCI-G98-1445
Record last reviewed:  February 2004
Last Updated:  October 13, 2004
Record first received:  November 1, 1999
ClinicalTrials.gov Identifier:  NCT00003367
Health Authority: United States: Federal Government
ClinicalTrials.gov processed this record on 2005-04-08


Source: ClinicalTrials.gov
Cache Date: April 9, 2005